Stephen Greene, MD

Stephen Greene, MD, is an associate professor of medicine at Duke University School of Medicine and cardiologist at the Duke Clinical Research Institute in Durham, NC. Greene is a member of HCPLive's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Articles by Stephen Greene, MD

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

Screen grab of both hosts from podcast episode

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

Screenshot from podcast episode

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

Thumbnail for episode 5 of the Don't Miss a Beat podcast

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.